Articles tagged "Non-invasive diagnosis"

2018 American Transplant Congress
The Efficacy of Laser Speckle Flowgraphy Device for Intraoperative Evaluation of Renal Blood Flow after Reperfusion
M. Muramatsu,¹ Y. Itabashi,¹ Y. Takahashi,² K. Sakurabayashi,¹ T. Mizutani,¹ Y. Hyodo,¹ Y. Hamasaki,² T. Kawamura,¹ K. Sakai,¹ S. Shishido.^1,2
¹Nephrology, Toho University Faculty of Medicine, Tokyo, Japan; ²Pediatric Nephrology, Toho University Faculty of Medicine, Tokyo, Japan.
Purpose:Laser speckle flowgraphy (LSFG) is a device to monitor cutaneous and ocular fundus blood flow. However, there is no report that the device was used…
2018 American Transplant Congress
mRNA Transcript Profiles of 14 Genes in Plasma Exosome Predict Risk for Antibody-Mediated Rejection (ABMR) of Renal Allografts
H. Zhang,¹ E. Huang,² C. Nast,³ J. Kahwaji,² A. Vo,² S. Jordan,² M. Toyoda.¹
¹Transplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA; ²Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; ³Pathology, Cedars-Sinai Medical Center, Los Angeles, CA.
Background: Previously we reported that mRNA transcript profiles of 4 genes (gp130, SH2D1B, TNFα and CCL4) in plasma exosome could predict the risk of ABMR,…
2018 American Transplant Congress
Diagnostic Accuracy of Non-Invasive Test of Hepatic Fibrosis in Liver Transplant Recipients
D. Galvez,¹ C. Bhati,¹ M. Siddiqui,² C. Schmoyer,² T. Arshad,² A. Sharma,¹ A. Cotterell,¹ K. Yadav,¹ T. Reichman,¹ M. Levy.¹
¹Department of Surgery, Virginia Commonwealth University Hospital, Richmond, VA; ²Department of Medicine, Virginia Commonwealth University Hospital, Richmond, VA.
Background & Aims: Hepatic fibrosis is an important predictor of liver- and non-liver related outcomes in patients with chronic liver disease (CLD) and liver transplantation…
2017 American Transplant Congress
Non-Invasive Detection of Rejection with ImmunoPET Imaging.
D. Mathews,¹ K. Lindsay,² P. Santangelo,² Y. Dong,¹ J. Tso,³ A. Adams.¹
¹Department of Surgery, Emory University, Atlanta, GA; ²Department of Biomedical Engineering, Georgia Tech, Atlanta, GA; ³JN Biosciences LLC, Mountain View, CA
Current approaches to detect and diagnose rejection are retrospective and/or invasive. These methods assess the extent of end organ damage by insensitive and non-specific measures…
2017 American Transplant Congress
Donor-Derived Cell-Free DNA Correlates with Antibody-Mediated Rejection in Kidney Allografts.
R. Bloom,¹ J. Bromberg,² E. Poggio,³ D. Hiller,⁴ R. Woodward,⁴ J. Sninsky,⁴ J. Yee,⁴ D. Brennan.⁵
¹University of Pennsylvania, Philadelphia, PA; ²University of Maryland, Baltimore, MD; ³Cleveland Clinic, Cleveland, OH; ⁴CareDx, Brisbane, CA; ⁵Washington University, St. Louis, MO
Purpose: Donor-derived cell-free DNA (dd-cfDNA) is a noninvasive test of allograft injury that may enable more frequent, quantitative, and safer assessment of allograft rejection and…
2017 American Transplant Congress
The Role of Urinary Chemokines in Distinguishing Causes of Renal Allograft Dysfunction.
S. Chong,¹ R. Fernando,² M. Harber,¹ C. Magee.¹
¹UCL Centre for Nephrology, Royal Free Hospital, London, United Kingdom; ²Anthony Nolan Laboratories, Royal Free Hospital, London, United Kingdom
The aetiology of renal transplant dysfunction is varied, and diagnosis often relies upon transplant biopsy, an invasive procedure that carries significant risk. Availability of a…
2017 American Transplant Congress
Donor-Derived Cell-Free DNA Is a Dynamic Biomarker of Active Rejection in Kidney Allografts.
D. Brennan,¹ J. Bromberg,² E. Poggio,³ D. Hiller,⁴ J. Sninsky,⁴ R. Woodward,⁴ J. Yee,⁴ R. Bloom.⁵
¹Washington University, St. Louis, MO; ²University of Maryland, Baltimore, MD; ³Cleveland Clinic, Cleveland, OH; ⁴CareDx, Brisbane, CA; ⁵University of Pennsylvania, Philadelphia, PA
Purpose: Donor-derived cell-free DNA (dd-cfDNA) has shown promise as a biomarker in identification of allograft rejection. Here we report on the changes in dd-cfDNA prior…
2017 American Transplant Congress
Donor-Derived Cell-Free DNA Normal Range and Biological Variation Defined in a Reference Population.
J. Bromberg,¹ D. Brennan,² E. Poggio,³ D. Hiller,⁴ R. Woodward,⁴ J. Yee,⁴ J. Sninsky,⁴ R. Bloom.⁵
¹University of Maryland, Baltimiore, MD; ²Washington University, St. Louis, MO; ³Cleveland Clinic, Cleveland, OH; ⁴CareDx, Brisbane, CA; ⁵University of Pennsylvania, Philadelphia, PA
Purpose: Donor-derived cell-free DNA (dd-cfDNA) in the circulating blood of transplant recipients has shown promise as a non-invasive biomarker of acute rejection. This analysis was…
2017 American Transplant Congress
Detection of Shared and Distinct Gene Expression Signatures in Tissue and Urine During Acute Rejection of Kidney Grafts.
K. Keslar,¹ A. Zmijewska,² J. Chen,² K. Newell,³ P. Heeger,⁴ R. Mannon,² R. Fairchild.¹
¹Department of Immunology, Cleveland Clinic, Cleveland, OH; ²Department of Medicine, Division of Nephrology, University of Alabama at Birmingham, Birmingham, AL; ³Department of Surgery, Emory University, Atlanta, GA; ⁴Department of Medicine, Translational Transplant Research Center, Icahn School of Medicine at Mount Sinai, New York, NY
A major goal of the Clinical Trials in Organ Transplantation (CTOT) studies is the identification of biomarkers that predict or diagnose acute graft rejection in…
2016 American Transplant Congress
Time Course of Hepatic Graft Function Improvement After Ledipasivir/Sofosbuvir Treatment in Liver Transplant Recipients with HCV and Fibrosis or Cirrhosis Who Achieved SVR.
S. Helmke,¹ J. O'Leary,² J. Burton,¹ M. Cookson,¹ S. Lauriski,¹ J. Trotter,² J. McHutchison,³ G. Everson.¹
¹University of Colorado, Aurora, CO; ²Baylor University Medical Center, Dallas, TX; ³Gilead Sciences, Inc., Foster City, CA.
Background: In SOLAR-1, liver transplant recipients with HCV and either fibrosis or cirrhosis were treated at baseline with ledipasvir/sofosbuvir and ribavirin for 12 or 24…